Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …

Single-cell technologies have described heterogeneity across tissues, but the spatial
distribution and forces that drive single-cell phenotypes have not been well defined …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …

Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

Purpose: Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive.
Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms (IPMNs) …

Prognostically relevant RNA expression states exist in pancreatic ductal adenocarcinoma
(PDAC), but our understanding of their drivers, stability, and relationship to therapeutic …

Pancreatic ductal adenocarcinoma (PDAC) belongs to the most lethal solid tumors in
humans. A histological hallmark feature of PDAC is the pronounced tumor microenvironment …

Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in
more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and …

Background The majority of pancreatic ductal adenocarcinomas (PDAC) are diagnosed at
the metastatic stage, and standard therapies have limited activity with a dismal 5-year …